1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Low Back Pain - Drugs In Development, 2022, provides an overview of the Low Back Pain (Central Nervous System) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Low back pain can happen anywhere below the ribs and above the legs. Causes of low back pain include overuse, strain, or injury, aging, arthritis, illness and cancer involving the spine. Symptoms include tingling or burning sensation, a dull achy feeling, or sharp pain and weakness in legs or feet. Treatment includes pain medications such NSAIDs (non-steroidal anti-inflammatory drugs) or opioids and muscle relaxants.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Low Back Pain - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Low Back Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Low Back Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Low Back Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 7, 17, 8, 9, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Low Back Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Low Back Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Low Back Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Low Back Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Low Back Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Low Back Pain (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Low Back Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Low Back Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Low Back Pain - Overview
- Low Back Pain - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Low Back Pain - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Low Back Pain - Companies Involved in Therapeutics Development
- Low Back Pain - Drug Profiles
- Low Back Pain - Dormant Projects
- Low Back Pain - Discontinued Products
- Low Back Pain - Product Development Milestones
- Featured News & Press Releases
- Jun 30, 2022: BioRestorative Therapies announces first patient enrolled for the company’s phase 2 clinical trial to treat chronic lumbar disc disease (cLDD)
- Jun 22, 2022: BioRestorative Therapies announces clinical trial contract with second site for the company’s phase 2 clinical trial to treat chronic lumbar disc disease (cLDD)
- Jun 13, 2022: BioRestorative Therapies announces clinical site initiation for the company’s phase 2 clinical trial to treat chronic lumbar disc disease (cLDD)
- Apr 29, 2022: BioRestorative Therapies hosts principal investigator meeting for its BRTX-100 phase 2 clinical trial to treat chronic lumbar disc disease
- Apr 18, 2022: BioRestorative Therapies announces selection of 10 clinical sites for its phase 2 clinical trial to treat chronic lumbar disc disease
- Apr 04, 2022: BioRestorative Therapies announces cGMP Cell Manufacturing Facility Certification
- Feb 16, 2022: Biorestorative Therapies announces notice of allowance on key patent for its BRTX-100 disc program
- Feb 07, 2022: BioRestorative Therapies announces it has initiated its phase 2 clinical trial to treat chronic lumbar disc disease
- Jan 04, 2022: BioRestorative Therapies awarded an STTR phase I grant to explore the therapeutic effects of PEG-Peptide hydrogel-encapsulated hypoxic bone marrow stem cells
- Aug 20, 2021: Notification of application for manufacturing and marketing approval of the additional indications of “low back pain, humeroscapular periarthritis, cervico-omo-brachial syndrome and tenosynovitis” for ZICTHORU Tapes (Transdermal, pain treatment NSAID patch, development code: HP-3150) in Japan
- Aug 19, 2021: BioRestorative Therapies awarded one of top 10 spine device companies by MedTech Outlook
- Jun 30, 2021: Mesoblast provides update on program for chronic low back pain due to degenerative disc disease
- Feb 17, 2021: AnGes’ phase 1b results of NF-kappa B Oligo DNA Decoy administration in subjects with chronic discogenic low back pain support advancement into phase 2 clinical study
- Feb 10, 2021: Mesoblast phase 3 trial shows that a single injection of Rexlemestrocel-L + Hyaluronic Acid carrier results in at least two years of pain reduction with opioid sparing activity in patients with chronic low back pain due to degenerative disc disease
- Dec 07, 2020: Notification of the results of Phase clinical study of HP-3150 for “low back pain, humeroscapular periarthritis, cervico-omo-brachial syndrome and tenosynovitis” in Japan (transdermal, pain treatment NSAID patch)
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Low Back Pain, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Companies, 2022 (Contd..1)
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Target, 2022 (Contd..1)
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Low Back Pain - Pipeline by Ache Laboratorios Farmaceuticos SA, 2022
- Low Back Pain - Pipeline by Adynxx Inc, 2022
- Low Back Pain - Pipeline by Allodynic Therapeutics LLC, 2022
- Low Back Pain - Pipeline by Amplicore Inc, 2022
- Low Back Pain - Pipeline by AnGes Inc, 2022
- Low Back Pain - Pipeline by Axsome Therapeutics Inc, 2022
- Low Back Pain - Pipeline by BioRestorative Therapies Inc, 2022
- Low Back Pain - Pipeline by Bol Pharma, 2022
- Low Back Pain - Pipeline by Camurus AB, 2022
- Low Back Pain - Pipeline by Causeway Therapeutics Ltd, 2022
- Low Back Pain - Pipeline by Creative Medical Technology Holdings Inc, 2022
- Low Back Pain - Pipeline by Daewon Pharmaceutical Co Ltd, 2022
- Low Back Pain - Pipeline by DongKoo Bio & Pharma Co Ltd, 2022
- Low Back Pain - Pipeline by Eli Lilly and Co, 2022
- Low Back Pain - Pipeline by Epione Therapeutics BV, 2022
- Low Back Pain - Pipeline by Ethismos Research Inc, 2022
- Low Back Pain - Pipeline by Evero Health Ltd, 2022
- Low Back Pain - Pipeline by Gador SA, 2022
- Low Back Pain - Pipeline by Hisamitsu Pharmaceutical Co Inc, 2022
- Low Back Pain - Pipeline by Imbrium Therapeutics LP, 2022
- Low Back Pain - Pipeline by Immune Pharmaceuticals Inc, 2022
- Low Back Pain - Pipeline by Indaptus Therapeutics Inc, 2022
- Low Back Pain - Pipeline by Laboratorios Silanes SA de CV, 2022
- Low Back Pain - Pipeline by MD Biosciences GmbH, 2022
- Low Back Pain - Pipeline by Mesoblast Ltd, 2022
- Low Back Pain - Pipeline by Navipharm Co Ltd, 2022
- Low Back Pain - Pipeline by Neumentum Inc, 2022
- Low Back Pain - Pipeline by Pacira BioSciences Inc, 2022
- Low Back Pain - Pipeline by Panacea Biotec Ltd, 2022
- Low Back Pain - Pipeline by Persica Pharmaceuticals Ltd, 2022
- Low Back Pain - Pipeline by Pfizer Inc, 2022
- Low Back Pain - Pipeline by Rebus Holdings Inc, 2022
- Low Back Pain - Pipeline by Scilex Holding Co, 2022
- Low Back Pain - Pipeline by Sclnow Biotechnology Co Ltd, 2022
- Low Back Pain - Pipeline by Shionogi & Co Ltd, 2022
- Low Back Pain - Pipeline by Spine BioPharma LLC, 2022
- Low Back Pain - Pipeline by Stayble Therapeutics AB, 2022
- Low Back Pain - Pipeline by Sun Pharma Advanced Research Company Ltd, 2022
- Low Back Pain - Pipeline by Tris Pharma Inc, 2022
- Low Back Pain - Pipeline by Valenta Pharm, 2022
- Low Back Pain - Pipeline by Vertanical GmbH, 2022
- Low Back Pain - Pipeline by WEX Pharmaceuticals Inc, 2022
- Low Back Pain - Pipeline by Xgene Pharmaceutical Inc, 2022
- Low Back Pain - Dormant Projects, 2022
- Low Back Pain - Dormant Projects, 2022 (Contd..1)
- Low Back Pain - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Low Back Pain, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Ache Laboratorios Farmaceuticos SA
- Adynxx Inc
- Allodynic Therapeutics LLC
- Amplicore Inc
- AnGes Inc
- Axsome Therapeutics Inc
- BioRestorative Therapies Inc
- Bol Pharma
- Camurus AB
- Causeway Therapeutics Ltd
- Creative Medical Technology Holdings Inc
- Daewon Pharmaceutical Co Ltd
- DongKoo Bio & Pharma Co Ltd
- Eli Lilly and Co
- Epione Therapeutics BV
- Ethismos Research Inc
- Evero Health Ltd
- Gador SA
- Hisamitsu Pharmaceutical Co Inc
- Imbrium Therapeutics LP
- Immune Pharmaceuticals Inc
- Indaptus Therapeutics Inc
- Laboratorios Silanes SA de CV
- MD Biosciences GmbH
- Mesoblast Ltd
- Navipharm Co Ltd
- Neumentum Inc
- Pacira BioSciences Inc
- Panacea Biotec Ltd
- Persica Pharmaceuticals Ltd
- Pfizer Inc
- Rebus Holdings Inc
- Scilex Holding Co
- Sclnow Biotechnology Co Ltd
- Shionogi & Co Ltd
- Spine BioPharma LLC
- Stayble Therapeutics AB
- Sun Pharma Advanced Research Company Ltd
- Tris Pharma Inc
- Valenta Pharm
- Vertanical GmbH
- WEX Pharmaceuticals Inc
- Xgene Pharmaceutical Inc
